HOME >> BIOLOGY >> NEWS
Other highlights in the May 19 JNCI

Two Studies Examine Safe Three Agent Combination Therapy for HER2-Positive Advanced Breast Cancer

Combinations of docetaxel, cisplatin or carboplatin, and the monoclonal antibody trastuzumab are feasible for the treatment of patients with HER2-positive advanced breast cancer in which tumor response rates are high, according to two new studies.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in the tumors of 20-30% of breast cancer patients and is associated with an increased risk of relapse and death in patients with early-stage breast cancer. In earlier clinical trials, adding trastuzumab, which blocks the effects of HER2, to standard chemotherapy increased both the response rate of patients and survival, but an unacceptable number of patients experienced cardiac dysfunction, including congestive heart disease.

In the first of two studies designed to find safer chemotherapy combinations that include trastuzumab, Mark D. Pegram, M.D., of the University of California, Los Angeles, and colleagues characterized the interactions between trastuzumab and nine chemotherapy drugs commonly used in treating breast cancer in four cell lines that overexpress HER2. They found synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine, which indicated that these were reasonable combinations to test in human clinical trials.

In the second study, a second group of researchers also led by Pegram, conducted two phase II clinical trials to evaluate the combination of docetaxel and trastuzumab with either of two platinum salts, cisplatin or carboplatin. In each trial, the combinations were tested on 62 women with advanced breast cancer that overexpressed HER2. Both combinations had a similar toxicity to docetaxel plus platinum salts alone, and there was a low incidence of cardiac dysfunction. In addition, overall response rates were higher. The combinations are now being tested
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
18-May-2004


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/6/2019)... ... November 06, 2019 , ... NDA Partners Chairman ... pharmaceutical industry executive with expertise in clinical pharmacology and pharmacometrics and a widely ... data analytics, has joined the firm as an Expert Consultant. , Dr. Stanski ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... solutions for drugs, biologics, gene therapies, and consumer health products, today announced it ... Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019. , On Wednesday, ...
(Date:11/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading ... so be sure to register today to save your place! Participate in the discussion ... upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging Technology and Data to ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... ... the many roles innovation and technology play in educating the next generation of ... hands-on learning opportunities and presentations by WesternU administrators and representatives of companies working ...
(Date:10/22/2019)... ... 22, 2019 , ... nQ Medical, Inc. of Cambridge, MA, was recognized in ... which was announced at a showcase event yesterday in Los Angeles. nQ competed against ... plans, and impressive near-term growth projections to be named one of the most fundable ...
(Date:10/17/2019)... ... 16, 2019 , ... My Gene Counsel , a ... a new white paper that explores how frequently medical management guidelines have been ... and medical providers can be kept informed as changes are made. , Entitled ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... network of clinical research centers in Europe. All Pratia research centers have completed ... to become trained and certified as Virtual Trial Capable and prepared to conduct ...
Breaking Biology Technology:
Cached News: